Development of a castrate resistant transplant tumor model of prostate cancer

Prostate

Volumn 72, Issue 6, 2012, Pages 587-591

  Ellis, Leigh ^a   Lehet, Kristin ^a   Ramakrishnan, Swathi ^a   Adelaiye, Remi ^a   Pili, Roberto ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

castrate resistant prostate cancer; mouse models; MYC; prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; MYC PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; GENETIC TRANSCRIPTION; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR MIMICRY; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; MALE; MICE; NEOPLASM TRANSPLANTATION; ORCHIECTOMY; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84858745800     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21465     Document Type: Article

References (11)

1. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL,. The current state of preclinical prostate cancer animal models. Prostate 2008; 68 (6): 629-639. (Pubitemid 351614641)
2. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H,. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4 (3): 209-221. (Pubitemid 37163835)
3. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL,. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4 (3): 223-238. (Pubitemid 37163836)
4. Jiao J, Wang S, Qiao R, Vivanco I, Watson PA, Sawyers CL, Wu H,. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 2007; 67 (13): 6083-6091. (Pubitemid 47037487)
5. Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL,. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 2005; 65 (24): 11565-11571. (Pubitemid 41821715)
6. Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA, Scott CL, Strasser A, Atadja P, Lowe SW, Johnstone RW,. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 2009; 114 (2): 380-393.
7. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, Smyth MJ, Johnstone RW,. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104 (19): 8071-8076. (Pubitemid 47185877)
8. Liao CP, Liang M, Cohen MB, Flesken-Nikitin A, Jeong JH, Nikitin AY, Roy-Burman P,. Mouse prostate cancer cell lines established from primary and post-castration recurrent tumors. Horm Cancer 2010; 1 (1): 44-54.
9. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23 (32): 8253-8261. (Pubitemid 46211563)
10. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10 (1): 33-39. (Pubitemid 38524696)
11. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL,. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324 (5928): 787-790.